Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial
-
Published:2024-01
Issue:
Volume:
Page:102383
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Lobo Suzana Margareth, Plantefève Gaétan, Nair Girish, Joaquim Cavalcante Adilson, Franzin de Moraes Nara, Nunes Estevao, Barnum Otis, Berdun Stadnik Claudio Marcel, Lima Maria PatelliORCID, Lins Muriel, Hajjar Ludhmila Abrahao, Lipinski Christopher, Islam Shaheen, Ramos Fabiano, Simon Tiago, Martinot Jean-Benoît, Guimard Thomas, Desclaux Arnaud, Lioger Bertrand, Neuenschwander Fernando Carvalho, DeSouza Paolino Bruno, Amin Alpesh, Acosta Samuel Amil, Dilling Daniel Forde, Cartagena Edgardo, Snyder Brian, Devaud Edouard, Barreto Berselli Marinho Ana KarolinaORCID, Tanni Suzana, Milhomem Beato Patricia Medeiros, De Wit Stephan, Selvan Vani, Gray Jeffrey, Fernandez Ricardo, Pourcher Valérie, Maddox Lee, Kay Richard, Azbekyan Anait, Chabane Mounia, Tourette Cendrine, Esmeraldino Luis Everton, Dilda Pierre J., Lafont René, Mariani Jean, Camelo SergeORCID, Rabut Sandrine, Agus SamuelORCID, Veillet Stanislas, Dioh Waly, van Maanen Rob, Morelot-Panzini Capucine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|